Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twinrix Antibody Persistence in Adolescents
NCT00197119Phase 3Completed
- Sponsor
- GSK
- Start
- May 2004
- Primary completion
- Jun 2004
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of hepatitis b vaccine recombinant in hepatitis A (HAV) and hepatitis B (HBV) (2 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentrations Above the Cut-off Value at Year 10, Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations Above the Cut-Off Value at Year 10 and 1 more. Started May 2004; status: completed.
02
Drugs
hepatitis b vaccine recombinant
03
Conditions
hepatitis A (HAV)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00197119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00197119.